Global Antidiabetic Sulphonylureas Market Size By Type (First Generation, The Second Generation), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Antidiabetic Sulphonylureas Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 2.3 billion by 2031, growing at a CAGR of 6.4% during the forecast period from 2023 to 2031. Sulphonylureas, a class of oral antidiabetic drugs, continue to play a pivotal role in the treatment of Type 2 diabetes mellitus due to their cost-effectiveness and proven efficacy. These agents stimulate insulin secretion from pancreatic β-cells and are often prescribed as monotherapy or in combination with other antidiabetic medications.

The market is driven by the increasing global prevalence of diabetes, especially in aging populations and emerging economies. Despite the emergence of newer drug classes, sulphonylureas retain a strong market presence due to their affordability, accessibility, and extensive clinical experience.

Drivers:

Rising Global Diabetes Burden:

According to international diabetes federations, over 537 million adults were living with diabetes in 2021, with numbers expected to rise significantly. Sulphonylureas remain a cornerstone therapy in many clinical settings, particularly in low- and middle-income countries.

Affordability and Wide Availability:

Compared to newer antidiabetic drugs like SGLT2 inhibitors and GLP-1 receptor agonists, sulphonylureas are more cost-effective and widely available, making them the preferred choice in price-sensitive healthcare systems.

Combination Therapy Popularity:

Sulphonylureas are frequently used in combination with metformin or insulin, which enhances glycemic control. The increasing trend of polypharmacy in diabetes management is supporting market demand.

Restraints:

Risk of Hypoglycemia and Weight Gain:

A well-documented limitation of sulphonylureas is the increased risk of hypoglycemia and weight gain, which has led many healthcare providers to prefer newer therapies with a more favorable safety profile.

Emergence of Advanced Therapeutics:

The rise of novel therapies that offer cardiovascular and renal benefits is gradually shifting preference away from sulphonylureas, especially in high-income regions.

Opportunity:

Expansion in Emerging Markets:

Rapid urbanization, dietary changes, and sedentary lifestyles in developing countries are increasing the incidence of Type 2 diabetes, presenting strong growth potential for sulphonylureas.

Generic Drug Penetration:

The widespread availability of generic versions of key sulphonylureas (such as glibenclamide, glipizide, and gliclazide) allows for deep market penetration in regions with constrained healthcare budgets.

Market by System Type Insights:

Based on system type, the Second-Generation Sulphonylureas segment held the dominant share in 2023. These include glimepiride and gliclazide, which are favored due to their improved pharmacokinetics and reduced side effect profiles compared to first-generation agents. This segment is expected to witness sustained demand, especially in primary care settings.

Market by End-use Insights:

In terms of end use, the Hospitals and Clinics segment accounted for the largest market share in 2023. These institutions are the primary distribution points for sulphonylureas, particularly in public health systems. The Retail Pharmacies segment is also gaining traction due to increasing patient self-management practices and over-the-counter availability in certain countries.

Market by Regional Insights:

Geographically, Asia-Pacific dominated the antidiabetic sulphonylureas market in 2023. The region's high diabetes burden, growing population, and government efforts to improve healthcare access drive significant demand. Meanwhile, Latin America and Africa are projected to register the highest growth rates during the forecast period due to rising awareness, improving diagnostics, and increased penetration of generic drugs.

Competitive Scenario:

Key players in the global antidiabetic sulphonylureas market include Sanofi S.A., Novartis AG, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Aurobindo Pharma, Glenmark Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, and Mylan N.V.

These companies are actively investing in expanding their generic drug portfolios, entering partnerships with public health institutions, and launching educational campaigns to promote medication adherence in diabetes treatment.

Scope of Work – Global Antidiabetic Sulphonylureas Market

Report Metric Details

Market Size (2023) USD 1.4 Billion

Projected Market Size (2031) USD 2.3 Billion

CAGR (2023–2031) 6.4%

Market Segments System Type (First-Gen, Second-Gen Sulphonylureas), End-use (Hospitals, Clinics, Pharmacies), Region

Growth Drivers Rising global diabetes prevalence, affordability, and inclusion in combination therapies

Opportunities Emerging market expansion, high generic drug penetration

Key Market Developments:

2023: Sanofi announced the continued expansion of its global access initiative for glimepiride in Southeast Asia to combat rising diabetes rates.

2024: Glenmark Pharmaceuticals introduced a new fixed-dose combination therapy including a sulphonylurea and metformin, aimed at improving compliance.

2025: Teva Pharmaceutical launched a low-cost, high-bioavailability version of gliclazide in African markets, targeting underserved diabetic populations.

FAQs:

What is the current market size of the Global Antidiabetic Sulphonylureas Market?

The market size was valued at USD 1.4 billion in 2023.

What is the major growth driver of the Global Antidiabetic Sulphonylureas Market?

The key driver is the rising global diabetes burden and the affordability of sulphonylureas.

Which is the largest region during the forecast period in the Global Antidiabetic Sulphonylureas Market?

Asia-Pacific is the largest and most rapidly growing regional market.

Which segment accounted for the largest market share in Global Antidiabetic Sulphonylureas Market?

The Second-Generation Sulphonylureas segment accounted for the largest market share in 2023.

Who are the key market players in the Global Antidiabetic Sulphonylureas Market?

Sanofi, Novartis, Glenmark, Aurobindo, Merck, Teva, and Dr. Reddy’s Laboratories are key players.